Prosonitron^TM, DISCUS^®, SAX^TM,  UMAX^® SAX^TM  and PRT based process technologies are proprietary "Solution-to-Particle" methods for controlling crystal size, shape and polymorph for APIs and helping in the making better medicines. The technologies offer dose-to-dose uniformity, formulation consistency, stability and the potential for 200 % + performance increase of inhaled APIs, as defined by fine particle fraction and delivered dose compared to micronized. In addition combination particles of multiple APIs can be manufactured.